- Home
- DVAX vs HUT Comparison
DVAX vs HUT Comparison
Compare DVAX & HUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- HUT
- Stock Information
- Founded
- DVAX 1996
- HUT 2011
- Country
- DVAX United States
- HUT United States
- Employees
- DVAX N/A
- HUT N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- HUT Finance: Consumer Services
- Sector
- DVAX Health Care
- HUT Finance
- Exchange
- DVAX Nasdaq
- HUT Nasdaq
- Market Cap
- DVAX 1.7B
- HUT 1.8B
- IPO Year
- DVAX 2004
- HUT N/A
- Fundamental
- Price
- DVAX $12.45
- HUT $26.92
- Analyst Decision
- DVAX Buy
- HUT Strong Buy
- Analyst Count
- DVAX 2
- HUT 8
- Target Price
- DVAX $23.00
- HUT $35.25
- AVG Volume (30 Days)
- DVAX 1.8M
- HUT 5.6M
- Earning Date
- DVAX 02-20-2025
- HUT 11-13-2024
- Dividend Yield
- DVAX N/A
- HUT N/A
- EPS Growth
- DVAX N/A
- HUT N/A
- EPS
- DVAX 0.15
- HUT 1.91
- Revenue
- DVAX $260,810,000.00
- HUT $194,021,000.00
- Revenue This Year
- DVAX $21.64
- HUT $41.71
- Revenue Next Year
- DVAX $19.81
- HUT $65.24
- P/E Ratio
- DVAX $82.38
- HUT $13.39
- Revenue Growth
- DVAX N/A
- HUT 209.07
- 52 Week Low
- DVAX $9.74
- HUT $6.18
- 52 Week High
- DVAX $14.30
- HUT $31.95
- Technical
- Relative Strength Index (RSI)
- DVAX 41.74
- HUT 57.38
- Support Level
- DVAX $12.27
- HUT $21.45
- Resistance Level
- DVAX $12.74
- HUT $27.20
- Average True Range (ATR)
- DVAX 0.35
- HUT 1.98
- MACD
- DVAX -0.06
- HUT 0.32
- Stochastic Oscillator
- DVAX 37.39
- HUT 73.60
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About HUT Hut 8 Corp.
Hut 8 Corp is engaged in the mining of digital assets with an operational focus on utilizing specialized equipment to solve complex computational problems to validate transactions on the Bitcoin blockchain and receiving Bitcoin in return for successful services. The company has four reportable business segments: Digital Assets Mining, Managed Services, High Performance Computing -Colocation and Cloud, and Other. It derives maximum revenue from Digital Assets Mining segment.